China Resources Jiangzhong Pharmaceutical Lifts 2025 Profit Despite Revenue Decline

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.

China Resources Pharmaceutical Group has announced that its consolidated subsidiary, Shanghai-listed China Resources Jiangzhong Pharmaceutical, reported unaudited preliminary financial results for 2025 showing a decline in revenue but solid profit growth. For the year ended 31 December 2025, Jiangzhong Pharmaceutical’s total operating revenue fell 4.87% year on year to RMB 4.2195 billion, yet operating profit rose 16.55% and net profit attributable to shareholders increased 14.96% to RMB 906.12 million, with earnings per share up 14.40% and return on net assets improving to 22.74%. Total assets and equity attributable to shareholders also grew modestly, indicating stronger profitability and capital efficiency despite softer top-line performance, which may enhance China Resources Pharmaceutical Group’s consolidated earnings and reinforce the subsidiary’s position in China’s pharmaceutical market.

The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate with a controlling effective interest in China Resources Jiangzhong Pharmaceutical Co., Ltd., a Shanghai-listed drug manufacturer in mainland China. Through its subsidiary China Resources Jiangzhong Pharmaceutical Group Co., Ltd., the Group consolidates Jiangzhong Pharmaceutical, which focuses on proprietary Chinese medicines and related pharmaceutical products for the domestic market.

Average Trading Volume: 12,791,893

Technical Sentiment Signal: Sell

Current Market Cap: HK$28.33B

For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.